[go: up one dir, main page]

PL1945631T3 - Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka - Google Patents

Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka

Info

Publication number
PL1945631T3
PL1945631T3 PL06794902T PL06794902T PL1945631T3 PL 1945631 T3 PL1945631 T3 PL 1945631T3 PL 06794902 T PL06794902 T PL 06794902T PL 06794902 T PL06794902 T PL 06794902T PL 1945631 T3 PL1945631 T3 PL 1945631T3
Authority
PL
Poland
Prior art keywords
aminopyrazole
cancer
treatment
tyrosine kinase
kinase inhibitors
Prior art date
Application number
PL06794902T
Other languages
English (en)
Inventor
Xiaomei Feng
Huiping Guan
Ying Kan
Stephanos Ioannidis
Bo Peng
Mei Su
Bin Wang
Tao Wang
Hai-Jun Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL1945631T3 publication Critical patent/PL1945631T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06794902T 2005-10-28 2006-10-26 Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka PL1945631T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73129905P 2005-10-28 2005-10-28
US80306106P 2006-05-24 2006-05-24
PCT/GB2006/003978 WO2007049041A1 (en) 2005-10-28 2006-10-26 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
EP06794902A EP1945631B8 (en) 2005-10-28 2006-10-26 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1945631T3 true PL1945631T3 (pl) 2012-12-31

Family

ID=37575154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06794902T PL1945631T3 (pl) 2005-10-28 2006-10-26 Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka

Country Status (22)

Country Link
US (3) US20080287475A1 (pl)
EP (2) EP1945631B8 (pl)
JP (1) JP2009513615A (pl)
KR (1) KR20080063846A (pl)
AR (1) AR056210A1 (pl)
AU (1) AU2006307657B2 (pl)
BR (1) BRPI0618011A2 (pl)
CA (1) CA2626375A1 (pl)
DK (1) DK1945631T3 (pl)
EC (1) ECSP088450A (pl)
ES (1) ES2391783T3 (pl)
HR (1) HRP20120824T1 (pl)
IL (1) IL190935A0 (pl)
MX (1) MX2008005398A (pl)
NO (1) NO20081893L (pl)
NZ (1) NZ567584A (pl)
PL (1) PL1945631T3 (pl)
PT (1) PT1945631E (pl)
RU (1) RU2463302C2 (pl)
TW (1) TW200800963A (pl)
UY (1) UY29886A1 (pl)
WO (1) WO2007049041A1 (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307667T3 (es) * 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.
PT1846394E (pt) * 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
CA2660758A1 (en) 2006-08-24 2008-02-27 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008061370A1 (en) * 2006-11-24 2008-05-29 Mcmaster University Diagnostic method to detect endometriosis
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
ATE521609T1 (de) * 2007-05-04 2011-09-15 Astrazeneca Ab Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA2692720A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
WO2009007753A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
CN101910152B (zh) 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
WO2009095712A2 (en) * 2008-01-29 2009-08-06 Astrazeneca Ab Chemical compounds
AU2009259026B2 (en) * 2008-06-11 2012-10-04 Astrazeneca Ab Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
UY32055A (es) * 2008-08-19 2010-03-26 Astrazeneca Ab Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
KR20110071098A (ko) * 2008-09-30 2011-06-28 아스트라제네카 아베 복소환 ｊａｋ 키나제 억제제
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
PE20140239A1 (es) 2010-10-07 2014-03-07 Takeda Pharmaceutical Derivados de 1,4-oxazepano
WO2012050141A1 (ja) * 2010-10-14 2012-04-19 住友化学株式会社 ヘテロ芳香環化合物およびその有害生物防除用途
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
EP2748159A1 (en) * 2011-08-25 2014-07-02 F.Hoffmann-La Roche Ag Serine/threonine pak1 inhibitors
CN103781779B (zh) * 2011-09-05 2016-06-08 浙江海正药业股份有限公司 具有蛋白激酶抑制活性的4-取代-(3-取代-1h-吡唑-5-氨基)-嘧啶衍生物及其用途
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8815877B2 (en) 2011-12-22 2014-08-26 Genentech, Inc. Serine/threonine kinase inhibitors
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
TW201618772A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
CN111848586B (zh) 2015-09-25 2024-05-03 迪哲(江苏)医药股份有限公司 用于抑制jak的化合物和方法
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
TWI759829B (zh) * 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426180A1 (de) * 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DK0970369T3 (da) * 1997-03-27 2002-01-28 Glatt Gmbh Fremgangsmåde til overvågning og/eller styring og regulering af en granulerings-, agglomererings-, instantiserings-, coating- og tørringsproces i en fluid bed eller bevæget .....
RU2249591C2 (ru) * 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
WO2000014552A1 (en) 1998-09-03 2000-03-16 Malcam Ltd. Moisture measurement device using microwaves
US6227041B1 (en) 1998-09-17 2001-05-08 Cem Corporation Method and apparatus for measuring volatile content
AU762523C (en) 1998-11-10 2004-02-12 Janssen Pharmaceutica N.V. HIV replication inhibiting pyrimidines
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
KR100820605B1 (ko) 1999-09-24 2008-04-08 얀센 파마슈티카 엔.브이. 항바이러스 조성물
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
US7034019B2 (en) 2000-05-08 2006-04-25 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
CZ2003468A3 (cs) 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
US7071217B2 (en) 2000-09-01 2006-07-04 Smithkline Beecham Corporation Substituted oxindole derivatives as tyrosine kinase inhibitors
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0303538A2 (hu) 2000-12-21 2005-02-28 Bristol-Myers Squibb Co. Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
SE0101675D0 (sv) 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
WO2003011855A2 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
CA2456187A1 (en) * 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
JP2005508337A (ja) 2001-09-27 2005-03-31 スミスクライン ビーチャム コーポレーション 化合物
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
MXPA06002608A (es) * 2002-12-20 2007-01-23 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
JP2007533717A (ja) 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7528138B2 (en) * 2004-11-04 2009-05-05 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006118231A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation シアノピリジン誘導体及びその医薬としての用途
JP2008540391A (ja) * 2005-05-05 2008-11-20 アストラゼネカ アクチボラグ ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
CN101316597B (zh) * 2005-11-03 2013-04-17 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
UY30444A1 (es) * 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
AU2006307657A1 (en) 2007-05-03
KR20080063846A (ko) 2008-07-07
BRPI0618011A2 (pt) 2011-08-16
EP2388259A1 (en) 2011-11-23
WO2007049041A8 (en) 2012-11-01
NZ567584A (en) 2011-08-26
EP1945631A1 (en) 2008-07-23
US8088784B2 (en) 2012-01-03
RU2008120848A (ru) 2009-12-10
UY29886A1 (es) 2007-05-31
EP1945631B8 (en) 2013-01-02
TW200800963A (en) 2008-01-01
JP2009513615A (ja) 2009-04-02
IL190935A0 (en) 2009-09-22
AR056210A1 (es) 2007-09-26
NO20081893L (no) 2008-05-20
CA2626375A1 (en) 2007-05-03
ECSP088450A (es) 2008-06-30
WO2007049041A1 (en) 2007-05-03
AU2006307657B2 (en) 2010-10-28
US20080287475A1 (en) 2008-11-20
HRP20120824T1 (hr) 2012-11-30
EP1945631B1 (en) 2012-08-08
DK1945631T3 (da) 2012-10-22
US20100160325A1 (en) 2010-06-24
US20120071480A1 (en) 2012-03-22
RU2463302C2 (ru) 2012-10-10
ES2391783T3 (es) 2012-11-29
MX2008005398A (es) 2008-09-24
PT1945631E (pt) 2012-10-15

Similar Documents

Publication Publication Date Title
IL190935A0 (en) 4-(3-aminopyrazole)pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IL174989A0 (en) 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer
ZA200901593B (en) Pyrimidines derivatives and their use as kinase inhibitors
IL195152A0 (en) Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
PL1761505T3 (pl) Pochodne pirymidynomocznika jako inhibitory kinazy
SI2120932T1 (sl) Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL186381A0 (en) Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
IL207224A0 (en) Pyrrolo [2,3-d] pyrimidines and use thereof as tyrosine kinase inhibitors
IL196998A0 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
PL2188289T3 (pl) (7H-pirolo[2,3-D]pirymidyn-4-ylo)-piperazyny jako inhibitory kinaz do leczenia nowotworów i zapalenia
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
ZA200606152B (en) 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
IL184997A0 (en) Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis
IL187895A0 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL185791A0 (en) Tyrosine kinase inhibitor compositions and methods for manufacturing and using them in the treatment of disease
ZA200902730B (en) Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer
ZA200704735B (en) Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis
ZA200803582B (en) 4-(3-Aminopyrazole) Pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met